Compare Cardinal Health Inc (CAH) vs TeraWulf Inc (WULF) Price & Performance

Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.

Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.

WULF stock trades at $17.69, up 9.2% on the day amid a broader rally in AI infrastructure stocks. The technical picture is bearish with key support at $16 and resistance at $18. Fundamentally, the company reported a Q2 2026 net loss of $1.94 per share, missing estimates, while revenue trends are stable. Despite negative profitability metrics, analyst sentiment remains unanimously bullish with a $38.00 consensus price target, driven by expansion in high-performance computing capacity.

The outlook hinges on execution of its HPC growth strategy, but significant risks include persistent losses, high capital expenditure, and exposure to regulatory shifts. The stock offers high upside if operational targets are met, yet carries substantial volatility and execution risk for investors.